Altimmune, Inc. - ALT STOCK NEWS

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two investor conferences in May 2022. The H.C. Wainwright Global Investment Conference is set for May 24 at 7:00 am Eastern Time, available via webcast. The B. Riley Securities Institutional Investor Conference will take place on May 26 at 1:00 pm Pacific Time, featuring an in-person fireside chat. Altimmune focuses on developing novel therapeutics for obesity and liver diseases, including its lead candidate, pemvidutide (ALT-801).

Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2022, showcasing ongoing clinical developments of pemvidutide, a dual receptor agonist for obesity. Notably, interim data from the Phase 2 MOMENTUM trial is expected in Q4 2022, with 10% weight loss observed after 12 weeks. However, revenue was minimal at $0.0 million, down from $0.8 million YoY, primarily due to halted projects. R&D expenses rose to $15.1 million, leading to a net loss of $19.4 million. The company holds $180 million in cash, offering a healthy runway for future trials.

Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its primary candidate being pemvidutide (ALT-801) for obesity and NASH treatment. Additionally, it is developing HepTcell™, aimed at treating chronic hepatitis B.

Altimmune, a clinical-stage biopharmaceutical company, announced the successful completion of enrollment in its 12-week Phase 1b trial of pemvidutide for non-alcoholic fatty liver disease (NAFLD) and the initiation of the 48-week Phase 2 MOMENTUM trial for obesity. The MOMENTUM trial aims to evaluate the safety and efficacy of pemvidutide, targeting approximately 320 non-diabetic subjects. Results from a prior Phase 1 trial indicated an average weight loss of 10.3%. Key data readouts are anticipated in Q3 and Q4 2022.

Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q4 and the full year of 2021, revealing a strong cash position of $190.3 million as of December 31, 2021. The company anticipates significant clinical data readouts over the next year, particularly from the pemvidutide (ALT-801) program, which showed promising results in weight loss and lipid reduction. The enrollment for the Phase 1b trial is over 90% complete, with data expected in Q3 2022. Revenue for Q4 2021 was $3.3 million, up from $2.3 million in Q4 2020, contributing to a net loss of $23.9 million for the quarter.

Altimmune, Inc. (Nasdaq: ALT) will report its fourth quarter and full year 2021 financial results on March 15, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), being developed for obesity and NASH. Additional developments include HepTcell™, an immunotherapeutic for chronic hepatitis B.

Altimmune, a clinical-stage biopharmaceutical company, has received FDA clearance for its IND application for the pemvidutide Phase 2 clinical trial targeting obesity. The trial is set to begin in Q1 2022, enrolling around 320 participants. Pemvidutide aims to treat obesity and has previously shown promising results, with a 10.3% average weight loss in a Phase 1 study. This trial will evaluate multiple dosages over 48 weeks, focusing on weight change and metabolic health. The company also develops treatments for non-alcoholic steatohepatitis (NASH).

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris, Chief Medical Officer, will present on pemvidutide, a dual receptor agonist targeting obesity and non-alcoholic steatohepatitis (NASH). The presentations will occur at the NASH-TAG Conference from January 6-8, 2022, in Park City, Utah. Dr. Harris will deliver an oral presentation on a placebo-controlled study of pemvidutide on January 8, 2022, at 8:10 am Mountain Time. The presentation details will be available on Altimmune's website post-conference, emphasizing the company's focus on innovative treatments for obesity and liver diseases.

Altimmune, Inc. (Nasdaq: ALT) announced the recruitment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. The Compensation Committee granted him equity awards under its 2018 Inducement Grant Plan, which includes options for 150,000 shares and 50,000 restricted stock units (RSUs). The exercise price for options will match the stock's closing price on the Grant Date. Vesting for these awards is contingent upon Mr. Eisenstadt’s continued employment, with full vesting occurring over four years.